Pub Date : 2023-01-26DOI: 10.1097/FM9.0000000000000174
Marta Maria Silva, Érica Alcântara Silva, Caline Novais Teixeira Oliveira, Maria Luísa Cordeiro Santos, Cláudio Lima Souza, Fabrício Freire de Melo, Márcio Vasconcelos Oliveira
Abstract Objective This review aimed to compile scientific data on the distribution and prevalence of group B Streptococcus (GBS) serotypes isolated from pregnant women across 30 countries from 2010 to 2019. Methods This was a systematic review that addresses the distribution and prevalence of GBS in pregnant women. The search included studies published between January 2010 and December 2019 in PubMed, Virtual Health Library (BVS), ScienceDirect, Scientific Electronic Library Online (SciELO), and LILACS databases. We also surveyed relevant articles published in English, Spanish, and Portuguese between February and April 2020. Original articles, communication, short report, theses, and dissertations were included. The prevalence of GBS colonization, method for capsular serotyping, antimicrobial resistance, distribution and prevalence of serotypes were extracted from each study. Results In all, 795 publications were identified. After applying the eligibility criteria, 48 articles were included for the final systematic analysis; most articles were from Asia and were published during the years 2014 to 2017. For the identification of serotypes, most studies used the polymerase chain reaction technique. There were records of all 10 GBS serotypes, namely, Ia, Ib, and II–IX, among the countries analyzed. GBS susceptibility and resistance to antibiotics were addressed in 37.5% of the publications analysed. Conclusion This review showed that GBS serotypes are distributed differently in the 30 analyzed countries, with serotypes Ia, Ib, and II to V being the most prevalent. Furthermore, our results highlighted the relationship of GBS with maternal colonization, implications for neonates, and antibiotic resistance.
{"title":"Distribution and Prevalence of Serotypes of Group B Streptococcus Isolated from Pregnant Women in 30 Countries: A Systematic Review","authors":"Marta Maria Silva, Érica Alcântara Silva, Caline Novais Teixeira Oliveira, Maria Luísa Cordeiro Santos, Cláudio Lima Souza, Fabrício Freire de Melo, Márcio Vasconcelos Oliveira","doi":"10.1097/FM9.0000000000000174","DOIUrl":"https://doi.org/10.1097/FM9.0000000000000174","url":null,"abstract":"Abstract Objective This review aimed to compile scientific data on the distribution and prevalence of group B Streptococcus (GBS) serotypes isolated from pregnant women across 30 countries from 2010 to 2019. Methods This was a systematic review that addresses the distribution and prevalence of GBS in pregnant women. The search included studies published between January 2010 and December 2019 in PubMed, Virtual Health Library (BVS), ScienceDirect, Scientific Electronic Library Online (SciELO), and LILACS databases. We also surveyed relevant articles published in English, Spanish, and Portuguese between February and April 2020. Original articles, communication, short report, theses, and dissertations were included. The prevalence of GBS colonization, method for capsular serotyping, antimicrobial resistance, distribution and prevalence of serotypes were extracted from each study. Results In all, 795 publications were identified. After applying the eligibility criteria, 48 articles were included for the final systematic analysis; most articles were from Asia and were published during the years 2014 to 2017. For the identification of serotypes, most studies used the polymerase chain reaction technique. There were records of all 10 GBS serotypes, namely, Ia, Ib, and II–IX, among the countries analyzed. GBS susceptibility and resistance to antibiotics were addressed in 37.5% of the publications analysed. Conclusion This review showed that GBS serotypes are distributed differently in the 30 analyzed countries, with serotypes Ia, Ib, and II to V being the most prevalent. Furthermore, our results highlighted the relationship of GBS with maternal colonization, implications for neonates, and antibiotic resistance.","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":"5 1","pages":"97 - 103"},"PeriodicalIF":0.0,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43032776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-26DOI: 10.1097/fm9.0000000000000182
Aleena M. Shajan, M. Nireekshan Kumar, P. Navaneethan, S. Danda, M. Beck
{"title":"An Unusual Case of BSND Gene–Related (Type IV) Bartter Syndrome Presenting as Antenatal Bartter Syndrome: A Case Report and Review of Literature","authors":"Aleena M. Shajan, M. Nireekshan Kumar, P. Navaneethan, S. Danda, M. Beck","doi":"10.1097/fm9.0000000000000182","DOIUrl":"https://doi.org/10.1097/fm9.0000000000000182","url":null,"abstract":"","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44744117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-05DOI: 10.1097/FM9.0000000000000178
Lingqun Hu, Plato J. Lysandrou, R. Minehart, Jing-Ping Wang, Y. Xia, Yiling Hu, Brett L. Worly
Abstract The care of obstetrics patients has improved dramatically over the past few decades. Unfortunately, rates of cesarean section remain high, and decreasing this rate requires close care and follow-up in the prenatal outpatient setting. Counseling regarding cesarean delivery and vaginal delivery is imperative. Opportunities still exist in helping patients objectively weigh the decision for cesarean delivery versus vaginal delivery. Additional developments have occurred in the intrapartum and the postpartum setting, with an aim to improve patient and neonatal outcomes. Changes have been implemented for patients undergoing cesarean delivery including preoperative and intraoperative treatment of pain, nausea, and vomiting, as well as postoperative care bundles that improve patient outcomes. Innovations have also occurred in the care of postpartum patients after vaginal delivery, again with improvements in patient outcomes. This article summarizes the current evidence, provides care recommendations, and identifies the next steps in improving obstetrics care.
{"title":"Care Bundles: Enhanced Recovery After Delivery","authors":"Lingqun Hu, Plato J. Lysandrou, R. Minehart, Jing-Ping Wang, Y. Xia, Yiling Hu, Brett L. Worly","doi":"10.1097/FM9.0000000000000178","DOIUrl":"https://doi.org/10.1097/FM9.0000000000000178","url":null,"abstract":"Abstract The care of obstetrics patients has improved dramatically over the past few decades. Unfortunately, rates of cesarean section remain high, and decreasing this rate requires close care and follow-up in the prenatal outpatient setting. Counseling regarding cesarean delivery and vaginal delivery is imperative. Opportunities still exist in helping patients objectively weigh the decision for cesarean delivery versus vaginal delivery. Additional developments have occurred in the intrapartum and the postpartum setting, with an aim to improve patient and neonatal outcomes. Changes have been implemented for patients undergoing cesarean delivery including preoperative and intraoperative treatment of pain, nausea, and vomiting, as well as postoperative care bundles that improve patient outcomes. Innovations have also occurred in the care of postpartum patients after vaginal delivery, again with improvements in patient outcomes. This article summarizes the current evidence, provides care recommendations, and identifies the next steps in improving obstetrics care.","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":"5 1","pages":"155 - 162"},"PeriodicalIF":0.0,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42695755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.1097/fm9.0000000000000181
Chen Wang, J. Juan, Huixia Yang
{"title":"A Summary of Chinese Guidelines on Diagnosis and Management of Hyperglycemia in Pregnancy (2022)","authors":"Chen Wang, J. Juan, Huixia Yang","doi":"10.1097/fm9.0000000000000181","DOIUrl":"https://doi.org/10.1097/fm9.0000000000000181","url":null,"abstract":"","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42671321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-19DOI: 10.1097/fm9.0000000000000180
Xinyu Shu, J. Juan, Huixia Yang
{"title":"Exploring the Optimal Diagnostic Thresholds of Hyperglycemia During Pregnancy","authors":"Xinyu Shu, J. Juan, Huixia Yang","doi":"10.1097/fm9.0000000000000180","DOIUrl":"https://doi.org/10.1097/fm9.0000000000000180","url":null,"abstract":"","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41972327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
To editor: Hypertriglyceridemia is a major risk factor for cardiovascular disease and acute pancreatitis. Accordingly, during pregnancy, the growing serum lipid levels have potentially critical implications. However, the management of gestational hypertriglyceridemia is further complicated because of the lack of safety data for most of the lipid-lowering agents. Here, we present a casewho is a young pregnant patient who developed very severe hypertriglyceridemia (>1000 mg/dL) and was successfully treated with insulin therapy plus fenofibrate in a timely and effectivemannerwithout noticeable adverse effects, with a purpose of providing a real-world approach or some references for obstetricians. The patient has given her consent to publish the clinical information and figures in the journal. A 32-year-old in vitro fertilization (IVF) multigravid woman, G3P0, in her regular antenatal care, at 30 weeks of gestation presented into the ward with complaints of onset of severe hypertriglyceridemia (HTG) on August 1, 2021. Her obstetric historywas significant for 2 spontaneous abortions. The patient andher husbandweredistantly related, and therewasno family history of lipid disorders. Her history was impressive for HTG pancreatitis, which occurred twice in the year 2011 and 2017, respectively. She was treated with an absolute diet as well as plasmapheresis for almost 1month when the first onset of pancreatitis was triggered byHTG,whichwas fueled by overindulgence in greasy foodwhen shewas 22years old.A recurrence of pancreatitis caused by overeating 6 years later compelled her to be admitted to another hospital again to receive some treatments, butwearenot able to secure enoughdetails.Allwe canapproach as she had been on exercise and taking fenofibrate 160 mg orally per day since the second outbreak, making her level of triglyceride (TG) range from 3 to 5 mmol/L until she
{"title":"Insulin Management for Hypertriglyceridemia in Pregnancy","authors":"De-cui Cheng, Jie Ma, Menghua Kuang, Cong Lu, Jianrogn Weng, Yuemin Yang, Xianming Xu","doi":"10.1097/FM9.0000000000000175","DOIUrl":"https://doi.org/10.1097/FM9.0000000000000175","url":null,"abstract":"To editor: Hypertriglyceridemia is a major risk factor for cardiovascular disease and acute pancreatitis. Accordingly, during pregnancy, the growing serum lipid levels have potentially critical implications. However, the management of gestational hypertriglyceridemia is further complicated because of the lack of safety data for most of the lipid-lowering agents. Here, we present a casewho is a young pregnant patient who developed very severe hypertriglyceridemia (>1000 mg/dL) and was successfully treated with insulin therapy plus fenofibrate in a timely and effectivemannerwithout noticeable adverse effects, with a purpose of providing a real-world approach or some references for obstetricians. The patient has given her consent to publish the clinical information and figures in the journal. A 32-year-old in vitro fertilization (IVF) multigravid woman, G3P0, in her regular antenatal care, at 30 weeks of gestation presented into the ward with complaints of onset of severe hypertriglyceridemia (HTG) on August 1, 2021. Her obstetric historywas significant for 2 spontaneous abortions. The patient andher husbandweredistantly related, and therewasno family history of lipid disorders. Her history was impressive for HTG pancreatitis, which occurred twice in the year 2011 and 2017, respectively. She was treated with an absolute diet as well as plasmapheresis for almost 1month when the first onset of pancreatitis was triggered byHTG,whichwas fueled by overindulgence in greasy foodwhen shewas 22years old.A recurrence of pancreatitis caused by overeating 6 years later compelled her to be admitted to another hospital again to receive some treatments, butwearenot able to secure enoughdetails.Allwe canapproach as she had been on exercise and taking fenofibrate 160 mg orally per day since the second outbreak, making her level of triglyceride (TG) range from 3 to 5 mmol/L until she","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":"5 1","pages":"47 - 50"},"PeriodicalIF":0.0,"publicationDate":"2022-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41684461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-08DOI: 10.1097/fm9.0000000000000177
A. Berger, J. Kowalczyk, P. Hess, Yunping Li
{"title":"Thrombotic Thrombocytopenic Purpura in a Parturient Leading to Life-Threatening Thrombocytopenia and Neonatal Demise—A Case Report","authors":"A. Berger, J. Kowalczyk, P. Hess, Yunping Li","doi":"10.1097/fm9.0000000000000177","DOIUrl":"https://doi.org/10.1097/fm9.0000000000000177","url":null,"abstract":"","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42857677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-27DOI: 10.1097/FM9.0000000000000169
Ke-yan Cheng, J. Cui, Wenli Zhou, Huiqiang Liu, Taotao Yang, Yonghong Wang
Abstract Objective The objective of this study was to investigate the expression levels of microRNA-141-5p(miRNA-141-5p), MAPK1 and neutrophil elastase in patients with and without preeclampsia (PE), and the relationship between miRNA-141-5p and MAPK1 with respect to the secretion of elastase by neutrophils in patients with PE. Methods Thirty patients with PE and 30 healthy pregnant (HP) women were recruited from The Second Hospital of Shanxi Medical University, Taiyuan, China, between February 2017 and July 2018. Neutrophils were isolated from 8 mL peripheral blood samples and cultured. We recorded neutrophil count and morphology during culture. Apoptosis was detected by flow cytometry in different groups at 0, 24, and 48 h. The expression levels of elastase were detected in neutrophils by enzyme-linked immunosorbent assay, whereas the expression levels of miRNA-141-5p in peripheral blood neutrophils were detected by real-time polymerase chain reaction. We used TargetScanHuman Release 7.2 to analyze the target genes of miRNA-141-5p. The expression of MAPK1 in peripheral blood neutrophils was detected by western blotting. Data were analyzed by SPSS version 21.0 software, and comparisons between groups were carried out with the Student t test. Results There was no significant difference between the PE and HP groups (P > 0.050) with regard to age or body mass index. The weight of newborns in the PE group (2846.00 ± 600.00 g) was significantly lower than that in the HP group (3055.00 ± 230.68 g). The number of neutrophilic granulocytes(NGs) in blood samples from the PE group was significantly higher than that in the HP group (P = 0.003). There was no significant difference between the groups with regard to morphology. Apoptosis in the PE group was delayed when compared with the HP group at different time points. The P value of apoptosis in the PE and HP groups were respectively 0.790, < 0.001 and 0.030 at 0 h, 24 h and 48 h. The expression levels of miRNA-141-5p in the PE group were significantly lower than those in the HP group (P < 0.050). The expression levels of MAPK1 in neutrophils from the PE group were significantly higher than those in the HP group (P < 0.050) by western blot. The expression levels of elastase in neutrophils from the PE group were significantly higher than those in the HP group (P < 0.050). Furthermore, the number of NGs in peripheral blood from the PE group was higher than that of the HP group; however, the levels of apoptosis were lower. The expression levels of miRNA-141-5p in NGs decreased, the expression of MAPK1 increased, and the secretion of neutrophil elastase in the NG medium increased in the PE group than those in the HP group. Conclusion Collectively, our analysis suggested that miRNA-141-5p may be involved in the pathogenesis of PE by regulating the MAPK1 signaling pathway to activate neutrophils and increase the secretion of elastase.
{"title":"miRNA-141-5p Affects the Levels of Neutrophil Elastase in Preeclampsia by Regulating MAPK1","authors":"Ke-yan Cheng, J. Cui, Wenli Zhou, Huiqiang Liu, Taotao Yang, Yonghong Wang","doi":"10.1097/FM9.0000000000000169","DOIUrl":"https://doi.org/10.1097/FM9.0000000000000169","url":null,"abstract":"Abstract Objective The objective of this study was to investigate the expression levels of microRNA-141-5p(miRNA-141-5p), MAPK1 and neutrophil elastase in patients with and without preeclampsia (PE), and the relationship between miRNA-141-5p and MAPK1 with respect to the secretion of elastase by neutrophils in patients with PE. Methods Thirty patients with PE and 30 healthy pregnant (HP) women were recruited from The Second Hospital of Shanxi Medical University, Taiyuan, China, between February 2017 and July 2018. Neutrophils were isolated from 8 mL peripheral blood samples and cultured. We recorded neutrophil count and morphology during culture. Apoptosis was detected by flow cytometry in different groups at 0, 24, and 48 h. The expression levels of elastase were detected in neutrophils by enzyme-linked immunosorbent assay, whereas the expression levels of miRNA-141-5p in peripheral blood neutrophils were detected by real-time polymerase chain reaction. We used TargetScanHuman Release 7.2 to analyze the target genes of miRNA-141-5p. The expression of MAPK1 in peripheral blood neutrophils was detected by western blotting. Data were analyzed by SPSS version 21.0 software, and comparisons between groups were carried out with the Student t test. Results There was no significant difference between the PE and HP groups (P > 0.050) with regard to age or body mass index. The weight of newborns in the PE group (2846.00 ± 600.00 g) was significantly lower than that in the HP group (3055.00 ± 230.68 g). The number of neutrophilic granulocytes(NGs) in blood samples from the PE group was significantly higher than that in the HP group (P = 0.003). There was no significant difference between the groups with regard to morphology. Apoptosis in the PE group was delayed when compared with the HP group at different time points. The P value of apoptosis in the PE and HP groups were respectively 0.790, < 0.001 and 0.030 at 0 h, 24 h and 48 h. The expression levels of miRNA-141-5p in the PE group were significantly lower than those in the HP group (P < 0.050). The expression levels of MAPK1 in neutrophils from the PE group were significantly higher than those in the HP group (P < 0.050) by western blot. The expression levels of elastase in neutrophils from the PE group were significantly higher than those in the HP group (P < 0.050). Furthermore, the number of NGs in peripheral blood from the PE group was higher than that of the HP group; however, the levels of apoptosis were lower. The expression levels of miRNA-141-5p in NGs decreased, the expression of MAPK1 increased, and the secretion of neutrophil elastase in the NG medium increased in the PE group than those in the HP group. Conclusion Collectively, our analysis suggested that miRNA-141-5p may be involved in the pathogenesis of PE by regulating the MAPK1 signaling pathway to activate neutrophils and increase the secretion of elastase.","PeriodicalId":74121,"journal":{"name":"Maternal-fetal medicine (Wolters Kluwer Health, Inc.)","volume":"4 1","pages":"238 - 244"},"PeriodicalIF":0.0,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44532318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}